RxDoctor Payments Data

Martha Menefee

Gerontology · Round Rock, TXNPI 1336524461

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.6% of the total across 623 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 21.8% — the pattern of someone who eats at a lot of different presentations. Among gerontology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$11,579in general payments, 2019–2025

Across 623 payments — averaging $18.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$3K
  • AbbVie$2K
  • Johnson & Johnson$2K
  • UCB, Inc.$969
  • Pfizer$824
  • AstraZeneca$819
  • plus $3K from 17 others

What the payments were for

  • Food & beverage$11,42099%
  • Education$1591%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,579 in reported general payments places this provider in the 95th percentile of 653 gerontology providers in Texas.

See all gerontology providers in Texas

Medicare billing

Part B allowed, 2024
$43,413
Medicare patients
175
Services billed
745

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab40$321,172
Orencia ClickjectAbatacept32$231,229
Enbrel SureclickEtanercept28$226,045
RinvoqUpadacitinib25$155,706
Enbrel MiniEtanercept16$135,289
Xeljanz XrTofacitinib Citrate21$118,812
Cyltezo(Cf) PenAdalimumab-Adbm12$82,154
Actemra ActpenTocilizumab17$64,194
Hydroxychloroquine Sulfate347$11,391
MethotrexateMethotrexate Sodium231$5,136
Leflunomide85$4,754
Celecoxib140$3,321
Cevimeline Hcl16$2,637
Prednisone352$2,211
Mycophenolate Mofetil21$1,921

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$1,803$155,70625 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 653 gerontology providers in Texas.

Other gerontology in Round Rock

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →